RxDoctor Payments Data

Blandina Sison, MD

Family Medicine · Houston, TXNPI 1447207592

Payments from drug & device makers

$12,784in general payments, 2019–2025

Across 742 payments — averaging $17.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AstraZeneca$1K
  • Amgen$927
  • Pfizer$810
  • Lilly USA, LLC$795
  • Amarin Pharma, Inc.$665
  • plus $6K from 52 others

What the payments were for

  • Food & beverage$12,784100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$12,784 in reported general payments places this provider in the 95th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$83,503
Medicare patients
196
Services billed
1,390

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide45$66,859
JardianceEmpagliflozin48$64,466
FarxigaDapagliflozin Propanediol30$33,646
JanuviaSitagliptin Phosphate24$33,116
EliquisApixaban23$31,307
TrulicityDulaglutide19$30,884
ProliaDenosumab15$24,982
MounjaroTirzepatide14$22,272
MyrbetriqMirabegron19$19,760
TradjentaLinagliptin15$14,689
Spiriva HandihalerTiotropium Bromide11$13,938
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog13$7,372
Tresiba Flextouch U-200Insulin Degludec14$6,477
Lantus SolostarInsulin Glargine,hum.Rec.Anlog23$4,342
Albuterol Sulfate HfaAlbuterol Sulfate160$4,224

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$395$79,15563 claims
Novo NordiskOzempic$2,007$66,85945 claims
Lilly USA, LLCTrulicity, Mounjaro$795$53,15633 claims
AstraZenecaFarxiga$1,147$33,64630 claims
MerckJanuvia$224$33,11624 claims
PfizerEliquis$810$31,30723 claims
AmgenProlia$927$24,98215 claims
Astellas Pharma US IncMyrbetriq$582$19,76019 claims
AbbVieSynthroid$337$1,25426 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →